Mechanisms of epigenetic deregulation in lymphoid neoplasms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.Signal transduction and targeted therapy · 2026
   Trial
2. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.Haematologica · 2017
   Trial
3. Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas.Cancers · 2022
   Review
4. BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression.American journal of cancer research · 2021
   Article
5. Alignment-free method for functional annotation of amino acid substitutions: Application on epigenetic factors involved in hematologic malignancies.PloS one · 2021
   Article
6. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell death & disease · 2020
   Review
7. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
   Review
8. Targeting epigenetic regulators in the treatment of T-cell lymphoma.Expert review of hematology · 2020
   Review
9. An investigation of methylation pattern changes in the IKZF1 promoter in patients with childhood B-cell acute lymphoblastic leukemia.Blood research · 2019
   Article
10. DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma.Scientific reports · 2017
    Article
11. Patterns of DNMT1 Promoter Methylation in Patients with Acute Lymphoblastic Leukemia.International journal of hematology-oncology and stem cell research · 2017
    Article
12. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Review
13. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.Oncotarget · 2016
    Article
14. The epigenetic basis of diffuse large B-cell lymphoma.Seminars in hematology · 2015
    Review
15. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Blood · 2015
    Article
16. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.British journal of haematology · 2013
    Article
17. Perspectives and future directions for epigenetics in hematology.Blood · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as